


03-18-03

AF/1600



DOCKET NO.: IBIS-0012

PATENT
RESPONSE UNDER 37 CFR § 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1634

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re Application of:

Ecker; Sampath; Griffey; and McNeil

Serial No.: 09/310,667

Filing Date: May 12, 1999

For: IDENTIFICATION OF MOLECULAR INTERACTION SITES IN RNA FOR
NOVEL DRUG DISCOVERY

Confirmation No.: 9164

MAR 20 2003

Group Art Unit: 1634

Examiner: Frank Wei Min Lu

TECH CENTER 1600/2900

EXPRESS MAIL LABEL NO: EV 252263135 US
DATE OF DEPOSIT: March 17, 2003

EV252263135US

Box ☐ NON-FEE
☒ AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

REPLY TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☒ An Amendment Responsive to the Office Action Dated January 15, 2003.
- ☐ An Amendment Supplemental to the Paper filed
- ☐ Other:
- ☒ Applicant(s) has previously claimed small entity status under 37 CFR § 1.27.
- ☐ Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR § 1.27 as:

DOCKET NO.: IBIS-0012

- 2 -

PATENT

- ☐ an Independent Inventor
- ☐ a Small Business Concern
- ☐ a Nonprofit Organization
- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the U.S. Patent and Trademark Office.
- ☐ Loss of Entitlement Enclosed
- ☐ Substitute Pages of the Specification are enclosed.
- ☐ An Abstract is enclosed.
- ☒ 2 Sheets of Proposed Corrected Drawings are enclosed.
- ☐ A Certified Copy of each of the following applications: is enclosed.
- ☐ An Associate Power of Attorney is enclosed.
- ☐ Information Disclosure Statement.
 - ☐ Attached Form 1449.
 - ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- ☐ Appended Material as follows: .
- ☐ Other Material as follows: .

FEE CALCULATION

☒ No Additional Fee is Due.

				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	35	35 (20 MINIMUM)	0	\$9 EACH	\$0	\$18 EACH	\$
INDEP. CLAIMS	5	6 (3 MINIMUM)	0	\$42 EACH	\$0	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$0	\$280	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$0	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$205	\$0	\$410	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$465	\$0	\$930	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$725	\$0	\$1450	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$985	\$0	\$1970	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$0)	minus	(\$)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$0	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$0		\$

- ☐ A check in the amount of \$.00 is attached. Please charge any deficiency or credit any overpayment to Deposit Account 23-3050.
- ☐ Petition is hereby made under 37 CFR § 1.136(a) (fees: 37 CFR § 1.17(a)(1)-(4) to extend the time for response to the Office Action of to and through comprising an extension of the shortened statutory period of month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to Deposit Account 23-3050. This sheet is provided in duplicate.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is provided in duplicate.
- ☐ The foregoing amount due for filing this paper.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 CFR § 1.16.

DOCKET NO.: IBIS-0012


- 4 -

PATENT

☒ Any additional patent application processing fees under 37 CFR § 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the U.S. Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: MARCH 17, 2003



Joseph Ducci
Registration No. 33,307

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2003 WW



DOCKET NO.: IBIS-0012

**PATENT
RESPONSE UNDER 37 CFR § 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1634**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ecker, Sampath, Griffey, and McNeil

Confirmation No. 9164

Serial No.: 09/310,667

Group Art Unit: 1634

Filed: May 12, 1999

Examiner: Frank Wei Min Lu

For: Identification Of Molecular Interaction Sites In RNA For Novel Drug Discovery

**EXPRESS MAIL LABEL NO: EV 252263135 US
DATE OF DEPOSIT: March 17, 2003**

BOX AF
Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND REQUEST FOR RECONSIDERATION

This is in response to the Final Rejection mailed January 15, 2003. Please amend the application as follows.

In the Figures

Please amend Figures 4 and 5A as presented in the attached pages.

In the Claims

Please amend claim 27 as follows.

27. An oligonucleotide comprising a molecular interaction site that is present in prokaryotic RNA and in at least one additional prokaryotic RNA, wherein said molecular interaction site serves as a binding site for at least one molecule that when bound to said molecular interaction